HAIR LOSS TREATMENT MARKET ANALYSIS

Hair Loss Treatment Market, By Product Type (Corticosteroids, Antihypertensive, Topical Immune-modulators, Others), By Type (Noncicatricial (Telogen Effluvium, Androgenetic Alopecia, Alopecia Areata), Cicatricial, Others), By Route of Administration (Oral, Topical), By Gender (Male, Female ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Oct 2023
Code : CMI4374
Pages :180
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Hair Loss Treatment Market: Key Developments

In September 2021, Dr. Reddy's Laboratories, a India-based multinational pharmaceutical company, launched prescription drug Minoxidil topical solution USP (U.S. Pharmacopeia) 2 % and 5 % for the treatment of female pattern hair loss in India. The company launched minoxidil topical solution under the brand name of Mintop 2 per cent and Mintop Eva 5 per cent, respectively.

On June 26, 2023, the U.S. Food and Drug Administration (FDA), announced that it had approved Ritlecitinib, a kinase inhibitor that inhibits Janus kinase 3 and tyrosine kinase for treatment of alopecia areata in individual of age 12 years and above.

In June 2021, Eli Lilly and Company, an U.S.-based multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved OLUMIANT (baricitinib), a once-daily pill, as a first-in-disease systemic treatment for adults with severe alopecia areata (AA), available as 4-mg, 2-mg and 1-mg tablets.